Patents by Inventor Jens Birktoft
Jens Birktoft has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090156624Abstract: The present invention provides methods of parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.Type: ApplicationFiled: January 29, 2008Publication date: June 18, 2009Applicant: Praecis Pharmaceuticals IncInventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
-
Patent number: 7405194Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: GrantFiled: March 24, 2006Date of Patent: July 29, 2008Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
-
Patent number: 7348307Abstract: The present invention provides methods of treating a lymphoma (e.g.Type: GrantFiled: May 3, 2006Date of Patent: March 25, 2008Assignee: Praecis Pharmaceuticals IncorporatedInventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
-
Patent number: 7268111Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: GrantFiled: September 27, 2005Date of Patent: September 11, 2007Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft
-
Publication number: 20070161570Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of inducing an immunosupressed condition and/or treating chronic allograft vasculopathy in a subject undergoing or who has undergone a transplant, by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.Type: ApplicationFiled: July 21, 2006Publication date: July 12, 2007Applicant: Praecis Pharmaceuticals, Inc.Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
-
Publication number: 20070117758Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: November 7, 2006Publication date: May 24, 2007Applicant: Praecis Pharmaceuticals, Inc.Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
-
Publication number: 20070010452Abstract: The present invention provides methods of parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.Type: ApplicationFiled: May 3, 2006Publication date: January 11, 2007Applicant: Praecis Pharmaceuticals, Inc.Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
-
Patent number: 7157420Abstract: The present invention provides methods of treating an autoimmune disorder (e.g., lupus erythematosus, multiple sclerosis, myasthenia gravis, vasculitis and diabetes mellitus) in a subject by administering to the subject a therapeutically effective amount of one or more compounds of the invention.Type: GrantFiled: October 8, 2004Date of Patent: January 2, 2007Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
-
Publication number: 20060223758Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: March 24, 2006Publication date: October 5, 2006Applicant: Praecis Pharmaceuticals, Inc.Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
-
Patent number: 7105482Abstract: The present invention provides methods of treating, parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.Type: GrantFiled: May 2, 2003Date of Patent: September 12, 2006Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
-
Patent number: 7084108Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: GrantFiled: November 1, 2001Date of Patent: August 1, 2006Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
-
Patent number: 7037890Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: GrantFiled: October 5, 2001Date of Patent: May 2, 2006Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
-
Publication number: 20060069028Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: September 27, 2005Publication date: March 30, 2006Applicant: Praecis Pharmaceuticals, Inc.Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft
-
Patent number: 6919307Abstract: The present invention provides methods of treating a parasitic infection, a lymphoid malignancy or an autoimmune disorder in a subject by administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising a MetAP-2 inhibitory core coupled to a peptide.Type: GrantFiled: May 2, 2002Date of Patent: July 19, 2005Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
-
Publication number: 20050130903Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: October 8, 2004Publication date: June 16, 2005Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
-
Publication number: 20050059585Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: May 2, 2003Publication date: March 17, 2005Applicant: Praecis Pharmaceuticals Inc.Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
-
Publication number: 20030109671Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: May 2, 2002Publication date: June 12, 2003Applicant: Praecis Pharmaceuticals Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
-
Publication number: 20020193298Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: October 5, 2001Publication date: December 19, 2002Applicant: Praecis Pharmaceuticals Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
-
Publication number: 20020151493Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: November 1, 2001Publication date: October 17, 2002Applicant: Praecis Pharmaceuticals Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel